Goldline Pharmaceutical Ltd544759Corporate

Latest results: Mar 2026 2 quarters of data

—

MCap —

Live price not available

Goldline Pharmaceutical Ltd — Stock analysis & AI research Goldline Pharmaceutical Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹17 Cr

Sales · Mar 2026

₹4 Cr

Operating Profit · Mar 2026

24.9%

OPM % · Mar 2026

₹3 Cr

Net Profit · Mar 2026

₹4.00

EPS · Mar 2026

📝 Goldline Pharmaceutical Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Goldline Pharmaceutical Ltd reported revenue of ₹17 crore for the quarter ended March 2026 (Q4 FY26).

Net profit stood at ₹3 crore. Earnings per share (EPS) came in at ₹4.00.

Operating profit stood at ₹4 crore — an operating margin (OPM) of 24.9%.

Shareholding pattern

As of May 2026, promoters held 57.29%, foreign institutional investors (FIIs) 5.16%, domestic institutional investors (DIIs) 7.81%, public shareholders 29.74% of Goldline Pharmaceutical Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

N/A

Current Price ?

N/A

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

29.9%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹17 Cr

PAT — latest qtr ?

₹3 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

17%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

119%

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹9 Cr

Debt to Equity ?

0.64

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

57.29%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

N/A

Return 6 months ?

N/A

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	14	17	—	—
Operating Profit	3	4	—	—
Other Income	0	0	—	—
Interest	1	1	—	—
Depreciation	0	0	—	—
Profit Before Tax	2	4	—	—
Net Profit	1	3	—	—
EPS	1.97	4.00	—	—
OPM %	19.0%	24.9%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	2.00	2.30	6.90	8.71	+26.2%
Reserves	2.08	3.76	1.65	5.54	+235.8%
Borrowings	12.64	12.94	12.85	9.16	-28.7%
Other Liabilities	2.67	3.93	4.88	5.46	+11.9%
Total Liabilities	19.39	22.93	26.28	28.87	+9.9%
Fixed Assets	2.50	2.95	2.89	2.71	-6.2%
CWIP	-0.00	0.45	-0.00	-0.00	—
Investments	0.07	0.03	0.04	0.03	-25.0%
Other Assets	16.82	19.50	23.35	26.13	+11.9%
Total Assets	19.39	22.93	26.28	28.87	+9.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	2.39	2.92	2.32	2.81	+21.1%
Cash from Investing Activity	-1.04	-1.11	0.16	-0.06	-137.5%
Cash from Financing Activity	-1.44	-1.08	-2.03	-3.40	-67.5%
Net Cash Flow	-0.09	0.74	0.45	-0.65	-244.4%
Free Cash Flow	1.38	1.81	2.49	2.75	+10.4%
CFO/OP	101%	72%	53%	55%	+3.8%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	159.65	149.54	139.30	188.70	+35.5%
Inventory Days	336.20	450.39	229.14	202.38	-11.7%
Days Payable	54.47	98.62	69.62	60.29	-13.4%
Cash Conversion Cycle	441.39	501.32	298.82	330.79	+10.7%
Working Capital Days	143.74	132.76	134.74	156.18	+15.9%
ROCE %	—	23.40%	29.21%	29.90%	+2.4%

👥 Shareholding (latest 1 periods)

Metric	May 2026	% Chg
Promoters	57.29%	—
FIIs	5.16%	—
DIIs	7.81%	—
Public	29.74%	—
No. of Shareholders	271	—

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.

❓ Frequently asked questions

What was Goldline Pharmaceutical Ltd's revenue in Q4 FY26?